Finch Announces Reverse Stock Split of Common Stock
June 09, 2023 07:00 ET
|
Finch Therapeutics Group, Inc.
BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of...
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
May 10, 2023 07:00 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...
Finch Therapeutics Announces Executive Leadership Transitions
April 25, 2023 16:05 ET
|
Finch Therapeutics Group, Inc.
Matthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO...
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
April 18, 2023 16:01 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 23, 2023 16:05 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...